BLCM Stock Price, Chart, Stats & News

Bellicum Pharmaceuticals, Inc.
Save
Bellicum Pharmaceuticals, Inc. (BLCM) does not currently pay a dividend.
778,326
Market cap
–
Current P/E
–
Forward P/E
BLCM chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations.
Similar securities
Based on sector and market capitalization
Report issue










